West Jefferson Medical Center

Recent papers from West Jefferson Medical Center

1. AMPLIFY: A phase 3 study of ⁶⁴ Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.Journal of Clinical Oncology · 2026
2. Treatment utilization among patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in real-world US settings: A prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
3. Real-world effectiveness of systemic therapies after [ ¹⁷⁷ Lu]Lu-PSMA-617 ( ¹⁷⁷ Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
4. Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate cancer.Journal of Clinical Oncology · 2026
5. Rescuing cancer immunotherapy with plasma exchange in bladder cancer 1 (ReCIPE-B1).Journal of Clinical Oncology · 2026
6. Outcomes of [ ¹⁷⁷ Lu]Lu-PSMA-617 ( ¹⁷⁷ Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
7. Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.Journal of Clinical Oncology · 2026
8. CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.Journal of Clinical Oncology · 2026
9. Extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) as potential biomarkers of response to ¹⁷⁷ Lu-PSMA-617.Journal of Clinical Oncology · 2026
10. Clinical outcomes among patients with metastatic hormone-sensitive prostate cancer in contemporary real-world US clinical practice: A prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
11. Real-world outcomes of [ ¹⁷⁷ Lu]Lu-PSMA-617 ( ¹⁷⁷ Lu-PSMA-617)in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
12. [ ¹⁷⁷ Lu]Lu-PSMA-617 ( ¹⁷⁷ Lu-PSMA-617) in combination with an androgen receptor pathway inhibitor (ARPI) versus ¹⁷⁷ Lu-PSMA-617 alone for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.Journal of Clinical Oncology · 2026
13. CHANTER syndrome in a cocaine positive patientRadiology Case Reports · 2025
14. Evaluation of Two Commercial Artificial Intelligence Segmentation Systems for Radiation TherapyJournal of Medical Physics · 2025
15. The NP and medication-assisted treatment for opioid use disorderThe Nurse Practitioner · 2022
16. Pilot phase results of a prospective, randomized controlled trial of narrowband ultraviolet B phototherapy in hospitalized COVID ‐19 patientsExperimental Dermatology · 2022
17. Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial VaginosisObstetrics and Gynecology · 2022
18. Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapyDrugs in Context · 2022
19. Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus MacaquesFrontiers in Immunology · 2021
20. A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19International Journal of Infectious Diseases · 2021